Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
Cancer Cell
    October 2017
  1. GULLUNI F, Martini M, De Santis MC, Campa CC, et al
    Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2alpha Scaffolding Function.
    Cancer Cell. 2017;32:444-459.
    >> Share

  2. ROBERTS KJ, Kershner AM, Beachy PA
    The Stromal Niche for Epithelial Stem Cells: A Template for Regeneration and a Brake on Malignancy.
    Cancer Cell. 2017;32:404-410.
    >> Share

    August 2017
  3. YATES LR, Knappskog S, Wedge D, Farmery JHR, et al
    Genomic Evolution of Breast Cancer Metastasis and Relapse.
    Cancer Cell. 2017;32:169-184.
    >> Share

  4. ZHAO X, Powers S
    New Views into the Genetic Landscape of Metastatic Breast Cancer.
    Cancer Cell. 2017;32:131-133.
    >> Share

    April 2017
  5. HYDBRING P, Wang Y, Fassl A, Li X, et al
    Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers.
    Cancer Cell. 2017;31:576-590.
    >> Share

    October 2016
  6. SHAN L, Zhou X, Liu X, Wang Y, et al
    FOXK2 Elicits Massive Transcription Repression and Suppresses the Hypoxic Response and Breast Cancer Carcinogenesis.
    Cancer Cell. 2016 Oct 14. pii: S1535-6108(16)30445.
    >> Share

    September 2016
  7. ZENG H, Qu J, Jin N, Xu J, et al
    Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer.
    Cancer Cell. 2016;30:459-73.
    >> Share

    March 2016
  8. HALBERG N, Sengelaub CA, Navrazhina K, Molina H, et al
    PITPNC1 Recruits RAB1B to the Golgi Network to Drive Malignant Secretion.
    Cancer Cell. 2016;29:339-53.
    >> Share

  9. JING H, Hu J, He B, Negron Abril YL, et al
    A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity.
    Cancer Cell. 2016;29:297-310.
    >> Share

  10. GOEL S, Wang Q, Watt AC, Tolaney SM, et al
    Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.
    Cancer Cell. 2016;29:255-69.
    >> Share

    January 2016
  11. LI JY, Perry SR, Muniz-Medina V, Wang X, et al
    A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.
    Cancer Cell. 2016;29:117-29.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016